The purpose of this Funding Opportunity Announcement (FOA) is to support high risk, high impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high risk, high impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated Go/No-Go criteria by the end of Year 2.

The purpose of this FOA is to support the establishment of multidisciplinary Tuberculosis (TB) Research Units (TBRUs) that will operate as a collaborative network to improve understanding of Mycobacterium tuberculosis (Mtb)-host interactions through characterization of bacterial and host determinants that are relevant during stages of infection and disease, and analyses of bacterial and host heterogeneity on disease outcomes.

The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.

The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.

The purpose of this Funding Opportunity is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis (TB) and viral hepatitis B and C. Applications are sought that lead to new effective therapies for administration once per month or less frequently as oral, injectable, implantable, or transdermal products.

This FOA solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities.

This Funding Opportunity Announcement (FOA) solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities.

This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention or treatment.

This NOFO supports integrated viral hepatitis surveillance and prevention programs in states and large cities in the United States. Key strategies include viral hepatitis outbreak planning and response; and surveillance for acute hepatitis A, B and C, and chronic hepatitis C. Applicants should develop a jurisdictional viral hepatitis elimination plan, promote comprehensive hepatitis B and C reporting, improve HBV and HCV testing policies, and increase healthcare providers trained to treat hepatitis B and C.

The Centers for Disease Control and Prevention (CDC) announces the availability of Fiscal Year (FY) 2020 funds for a cooperative agreement with organizations with demonstrated experience and capacity of implementing community engagement methods and multi-sector partnerships to promote sexual health, advance community wellness, influence sexual health behavior and practices, and reduce STI disparities.